EP0751960A4 - Epitopes de lymphocytes t inverses ou retro-inverses synthetiques - Google Patents

Epitopes de lymphocytes t inverses ou retro-inverses synthetiques

Info

Publication number
EP0751960A4
EP0751960A4 EP95910335A EP95910335A EP0751960A4 EP 0751960 A4 EP0751960 A4 EP 0751960A4 EP 95910335 A EP95910335 A EP 95910335A EP 95910335 A EP95910335 A EP 95910335A EP 0751960 A4 EP0751960 A4 EP 0751960A4
Authority
EP
European Patent Office
Prior art keywords
inverso
retro
synthetic
cell epitopes
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95910335A
Other languages
German (de)
English (en)
Other versions
EP0751960A1 (fr
Inventor
Alfio Comis
Margaret Isabel Tyler
Peter Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deakin Research Pty Ltd
Original Assignee
Deakin Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deakin Research Pty Ltd filed Critical Deakin Research Pty Ltd
Publication of EP0751960A1 publication Critical patent/EP0751960A1/fr
Publication of EP0751960A4 publication Critical patent/EP0751960A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP95910335A 1994-02-25 1995-02-24 Epitopes de lymphocytes t inverses ou retro-inverses synthetiques Withdrawn EP0751960A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPM4119A AUPM411994A0 (en) 1994-02-25 1994-02-25 Epitopes
AUPM4119/94 1994-02-25
PCT/AU1995/000090 WO1995023166A1 (fr) 1994-02-25 1995-02-24 Epitopes de lymphocytes t inverses ou retro-inverses synthetiques

Publications (2)

Publication Number Publication Date
EP0751960A1 EP0751960A1 (fr) 1997-01-08
EP0751960A4 true EP0751960A4 (fr) 1998-04-29

Family

ID=3778735

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95910335A Withdrawn EP0751960A4 (fr) 1994-02-25 1995-02-24 Epitopes de lymphocytes t inverses ou retro-inverses synthetiques

Country Status (6)

Country Link
EP (1) EP0751960A4 (fr)
JP (1) JPH09509182A (fr)
AU (1) AUPM411994A0 (fr)
CA (1) CA2183977A1 (fr)
WO (1) WO1995023166A1 (fr)
ZA (1) ZA951591B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1277057B1 (it) * 1995-12-11 1997-11-04 Tecnogen Scpa Peptidi antigenici migliorati
WO1997021728A1 (fr) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE FIXANT LA SEQUENCE KLVFF DE L'AMYLOIDE $g(b)
FR2763071B1 (fr) * 1997-05-07 2003-05-16 Centre Nat Rech Scient Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CA2317674A1 (fr) * 1998-01-08 1999-07-15 William Clifford Duckworth Methodes et compositions permettant de traiter et de diagnostiquer les troubles lies a l'insuline
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
KR100879810B1 (ko) 2000-02-21 2009-01-22 하. 룬드벡 아크티에셀스카브 아밀로이드의 하향-조절을 위한 신규한 방법
WO2001062284A2 (fr) * 2000-02-21 2001-08-30 Pharmexa A/S Nouvelle methode de regulation negative d'amyloide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
CA2590337C (fr) 2004-12-15 2017-07-11 Neuralab Limited Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
GB0520068D0 (en) * 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN104744564B (zh) * 2015-03-13 2017-07-28 天津托普泰克生物科技有限公司 抗乙型肝炎病毒x蛋白多肽药物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282891A2 (fr) * 1987-03-19 1988-09-21 ENIRICERCHE S.p.A. Thymopentine rétro-inverso analogues et leurs fragments, leur procédé de préparation et intermédiaires ainsi obtenus
WO1991013909A1 (fr) * 1990-03-15 1991-09-19 Proteus Molecular Design Limited Polypeptides synthetiques
WO1993011155A1 (fr) * 1991-12-03 1993-06-10 Proteus Molecular Design Limited Fragments de proteines de prion
WO1993021218A1 (fr) * 1992-04-16 1993-10-28 Proteus Molecular Design Limited Polypeptides synthetiques derives de la glycoproteine d'enveloppe du vih

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2143823C (fr) * 1992-08-27 2005-07-26 Alfio Comis Analogues synthetiques de peptides, modifies pour la reversion, l'inversion et la reversion-inversion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282891A2 (fr) * 1987-03-19 1988-09-21 ENIRICERCHE S.p.A. Thymopentine rétro-inverso analogues et leurs fragments, leur procédé de préparation et intermédiaires ainsi obtenus
WO1991013909A1 (fr) * 1990-03-15 1991-09-19 Proteus Molecular Design Limited Polypeptides synthetiques
WO1993011155A1 (fr) * 1991-12-03 1993-06-10 Proteus Molecular Design Limited Fragments de proteines de prion
WO1993021218A1 (fr) * 1992-04-16 1993-10-28 Proteus Molecular Design Limited Polypeptides synthetiques derives de la glycoproteine d'enveloppe du vih

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
G. GUICHARD ET AL.: "Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, October 1994 (1994-10-01), WASHINGTON US, pages 9765 - 9769, XP002054075 *
See also references of WO9523166A1 *

Also Published As

Publication number Publication date
AUPM411994A0 (en) 1994-03-24
JPH09509182A (ja) 1997-09-16
WO1995023166A1 (fr) 1995-08-31
CA2183977A1 (fr) 1995-08-31
ZA951591B (en) 1995-12-08
EP0751960A1 (fr) 1997-01-08

Similar Documents

Publication Publication Date Title
EP0751960A4 (fr) Epitopes de lymphocytes t inverses ou retro-inverses synthetiques
GB9619232D0 (en) Cytotoxic T-cell epitopes
GB2266538B (en) Frayless natural fabric
EP0448099A3 (en) Novel peptides
CA2049534C (fr) Couvre-boyau
GB9105569D0 (en) N-acylated cyclohexapeptide compounds
GB9111291D0 (en) Diagnostic peptides
EP0746565A4 (fr) Nouveaux peptides apparentes a la bombesine
GB2257356B (en) Seat cover
HU904871D0 (en) Biocidal preparative
GB9016810D0 (en) Peptides
GB9413751D0 (en) Immunodominant peptides
EP0521918A4 (en) Anti-tumour peptides
GB9618673D0 (en) The use of muramyl peptides
GB9425381D0 (en) Peptides
EP0699398A3 (fr) Vêtement à éléments détachables
GB9021439D0 (en) Improved clamp
GB9411466D0 (en) Zip up quilt cover
HU906318D0 (en) Diagnostic preparative
AU129880S (en) Canister top
GB9028140D0 (en) Peptides
ZA917211B (en) File cover
GB9305136D0 (en) Improved upholstery fabric
GB9025751D0 (en) Pushdry invention
AU127389S (en) Fabric

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960919

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 960919;SI PAYMENT 960919

A4 Supplementary search report drawn up and despatched

Effective date: 19980311

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000901